RFL:NYE-Rafael Holdings, Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 50.52

Change

-1.42 (-2.73)%

Market Cap

USD 0.92B

Volume

0.07M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Rafael Holdings, Inc. owns commercial real estate assets and interests in pre-clinical and clinical stage pharmaceutical companies. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

-0.59 (-0.66%)

USD203.75B 30.40 3.38
BHVN Biohaven Pharmaceutical Holdin..

-2.39 (-1.91%)

USD8.15B N/A N/A
RCUS Arcus Biosciences, Inc

+1.29 (+4.07%)

USD2.27B N/A N/A
MYOV Myovant Sciences Ltd

+0.50 (+2.45%)

USD1.87B N/A N/A
ADCT ADC Therapeutics SA

-0.47 (-2.09%)

USD1.76B -99,999.99 N/A
ZYME Zymeworks Inc

-0.84 (-2.27%)

USD1.71B 300.20 N/A
ANVS Annovis Bio, Inc

-3.89 (-3.50%)

USD0.77B -99,999.99 N/A
AMAM Ambrx Biopharma Inc

N/A

USD0.70B N/A N/A
PFNX Pfenex Inc

N/A

USD0.44B 268.67 63.90
LCTX Lineage Cell Therapeutics, Inc

-0.07 (-2.55%)

USD0.42B 3.63 N/A

ETFs Containing RFL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 116.64% 96% A 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 116.64% 96% A 97% A+
Trailing 12 Months  
Capital Gain 252.55% 96% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 252.55% 96% A 97% A+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 44.09% 68% D+ 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.09% 68% D+ 94% A
Risk Return Profile  
Volatility (Standard Deviation) 94.50% 29% F 7% F
Risk Adjusted Return 46.66% 50% F 57% F
Market Capitalization 0.92B 79% C+ 49% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 7.43 33% F 14% F
Price / Cash Flow Ratio -197.19 100% A+ 97% A+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -12.88% 92% A- 21% F
Return on Invested Capital -7.00% 75% C 14% F
Return on Assets -5.66% 93% A 8% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.80 32% F 12% F
Short Percent 5.83% 54% F 36% F
Beta 2.34 21% F 8% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector